THYQUIDITY (LEVOTHYROXINE SODIUM) ORAL SOLUTION 100 MCG/5ML

Serial Number 90350942
606

Registration Progress

Application Filed
Dec 1, 2020
Under Examination
Apr 5, 2022
Approved for Publication
Feb 8, 2022
Published for Opposition
Feb 8, 2022
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: THYQUIDITY (LEVOTHYROXINE SODIUM) ORAL SOLUTION 100 MCG/5ML
Previous Owner: AZURITY PHARMACEUTICALS, INC.
Classes: 005

Trademark Image

THYQUIDITY (LEVOTHYROXINE SODIUM) ORAL SOLUTION 100 MCG/5ML

Basic Information

Serial Number
90350942
Filing Date
December 1, 2020
Published for Opposition
February 8, 2022
Abandonment Date
May 8, 2023
Drawing Code
3

Status Summary

Current Status
Inactive
Status Code
606
Status Date
May 8, 2023
Classes
005

Rights Holder

AZURITY PHARMACEUTICALS, INC.

03
Address
8 CABOT ROAD
SUITE 2000
WOBURN, MA 01801

Ownership History

VistaPharm, Inc.

Original Applicant
03
New Providence, NJ

VistaPharm, Inc.

Owner at Publication
03
New Providence, NJ

AZURITY PHARMACEUTICALS, INC.

New Owner After Publication #1
03
WOBURN, MA

Legal Representation

Attorney
Maury M. Tepper, III

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

27 events
Date Code Type Description Documents
May 8, 2023 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
May 8, 2023 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 19, 2022 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Oct 6, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 4, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 4, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 4, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 3, 2022 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Apr 5, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 8, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 8, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 19, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 6, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 6, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 6, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 6, 2022 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jan 6, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 16, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 16, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 16, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 19, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 19, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 19, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 18, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 6, 2021 MDSM E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Feb 5, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Dec 4, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for the treatment of hypothyroidism, thyroid hormone deficiency, myxedema and thyroid tumors

Additional Information

Design Mark
The mark consists of a stylized infinity symbol followed by the text THYQUIDITY above the text "(LEVOTHYROXINE SODIUM)" above the text "100MGC/5ML".
Pseudo Mark
THYQUIDITY (LEVOTHYROXINE SODIUM) ORAL SOLUTION ONE HUNDRED MICRO GRAMS FIVE MILLILITERS; THYQUDITY (LEVOTHYROXINE SODIUM) ORAL SOLUTION ONE ZERO ZERO MICROGRAM/FIVE MILLILITERS

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"(LEVOTHYROXINE SODIUM) ORAL SOLUTION 100 MCG/5ML"